Related Experiment Video
Updated: Aug 25, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Inhibition of p53 degradation by Mdm2 acetylation
Xinjiang Wang1, Jan Taplick, Naama Geva
1Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel.
Abstract:
Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation. We now report that Mdm2 is also a target for acetylation. Mdm2 is acetylated in vitro by CREB-binding protein (CBP) and to a lesser extent by p300, but not by p300/CPB-associated factor. Acetylation occurs primarily within the RING finger domain of Mdm2. In vivo acetylation of Mdm2 was detected easily with CBP but not p300. Efficient in vivo acetylation required the preservation of the RING finger. An Mdm2 mutant (K466/467Q) mimicking acetylation is impaired in its ability to promote p53 ubiquitination, as well as Mdm2 autoubiquitination. Moreover, K466/467Q is defective in promoting p53 degradation in living cells. We thus suggest that acetyltransferases may modulate cellular p53 activity not only by modifying p53, but also by inactivating Mdm2.
Insights
Mdm2, a protein that degrades p53, is itself acetylated by CBP and p300. This acetylation, particularly in the RING finger domain, impairs Mdm2
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Mdm2 (mouse double minute 2 homolog) is a RING finger E3 ubiquitin ligase.
- Mdm2 targets the p53 tumor suppressor protein for ubiquitination and proteasomal degradation.
- Acetylation of p53 influences its transcriptional activity and inhibits Mdm2-mediated degradation.
Purpose of the Study:
- To investigate whether Mdm2 is also a target of acetylation.
- To determine the functional consequences of Mdm2 acetylation on p53 regulation.
Main Methods:
- In vitro acetylation assays using purified proteins and cell extracts.
- Identification of acetylation sites and domains within Mdm2.
- In vivo acetylation studies in cells.
- Analysis of Mdm2 activity using a mutant mimicking acetylation (K466/467Q).
Main Results:
- Mdm2 is acetylated in vitro by CREB-binding protein (CBP) and p300, primarily in the RING finger domain.
- In vivo acetylation of Mdm2 is efficiently mediated by CBP and requires an intact RING finger.
- An Mdm2 mutant mimicking acetylation (K466/467Q) shows impaired p53 ubiquitination, Mdm2 autoubiquitination, and p53 degradation.
Conclusions:
- Mdm2 is a novel target for acetylation by CBP and p300.
- Acetylation of Mdm2, particularly within the RING finger domain, inactivates its E3 ligase activity.
- Acetyltransferases can modulate cellular p53 activity by directly acetylating and inactivating Mdm2, in addition to acetylating p53.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Inhibition of Cdk Activity
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.

